Medicare expands coverage for Alzheimer's treatments, including new drugs.

Medicare Part B will cover Alzheimer's disease treatments that receive FDA approval, including new antibody treatments such as Leqembi, once the FDA approves them. Patients will have to participate in registries that collect real-world data on how the drugs work. The expanded coverage policy will apply to any other Alzheimer's antibody treatment that receives full approval from the FDA. The Alzheimer's Association has called on Medicare to drop restrictions on Leqembi and fully cover the drug. A study projected Leqembi could cost Medicare up to $5 billion a year.